Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety, tolerability, and pharmacokinetics study of NTX-083 in healthy adult males
jRCT2031240660Phase 1Completed
- Sponsor
- Not applicable
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing NTX-083 arm with Placebo arm (2 arms). Primary endpoints: Safety and tolerability of NTX-083 and Pharmacokinetics of NTX-083. Started Feb 2025; status: completed.
02
Drugs
NTX-083
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240660.